Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Drug Review Review Pathway United States

GDUFA II Will Include Small Business Relief, Priority ANDA Reviews

  • Analysis

Executive Summary

Generics industry and FDA have resolved remaining issues regarding financing of user fee program.

You may also be interested in...



'Bridging' Of Generic Review Goal Dates Makes Progress At US FDA

Assigning official goal dates to ANDAs that hadn't been included in GDUFA began in mid-October and already has lead to approvals.

'Bridging' Of Generic Review Goal Dates Makes Progress At US FDA

Assigning official goal dates to ANDAs that hadn't been included in GDUFA began in mid-October and already has lead to approvals.

Califf Optimistic As He Departs US FDA

Outgoing commissioner highlights efforts to improve staff, says bucket list mostly accomplished. Agency now faces hiring freeze challenge.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Related Companies

Tags:
Drug Review Review Pathway United States
Latest Headlines

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

German HTA Queries Polivy Benefits Amid Lack Of Evidence

See All
UsernamePublicRestriction

Register

PS119044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By